Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904514 | 0.84 | TSHR (0.45) | NOS2HTTKMT2A | |
| SCHEMBL904606 | 0.84 | HPGD (0.46) | NOS2GRIN2BMEN1KMT2AKDM4E | |
| SCHEMBL904820 | 0.83 | HPGD (0.47) | NOS2MEN1KMT2AKDM4EGAA | |
| SCHEMBL904400 | 0.83 | NOS2 (0.46) | NOS2GRIN2BKDM4EHRH3 | |
| SCHEMBL904460 | 0.82 | RAB9A (0.44) | NOS2KDM4E | |
| SCHEMBL904574 | 0.82 | CYP2D6 (0.43) | GRIN2BCYP2D6CYP2C9 | |
| SCHEMBL904534 | 0.81 | CNR2 (0.46) | NOS2GRIN2BHRH3 | |
| SCHEMBL904457 | 0.80 | ALDH1A1 (0.45) | NOS2GRIN2BKMT2AKDM4EHRH3 | |
| SCHEMBL904582 | 0.80 | NOS1 (0.41) | NOS2KDM4ENOS3NOS1 | |
| SCHEMBL904611 | 0.78 | FAAH (0.46) | NOS2GRIN2BMEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621899-B1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-10-21 | — | — | EP | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| EP-2621899-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044046-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | OPRK1, OPRM1, OPRL1 | NOS2 1768/4885GRIN2B 119/4885MEN1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.